SEP 16, 2014 09:30 AM PDT
Analysis of Oncomine Knowledgebase to identify NFE2L2 pathway as a novel therapeutic opportunity in multiple cancer types
18 46 1450

Speakers:
  • Staff Scientist, Bioinformatics, Thermo Fisher Scientific
    Biography
      Dr. Khazanov works as a Bioinformatics Scientist on the Compendia Bioscience™ Translational Bioinformatics Services team, part of Thermo Fisher Scientific. In this role, Dr. Khazanov works with translational scientists to identify potential novel drug targets and to characterize drug-response biomarkers using large sets of data from tumor samples. He earned his doctorate in Bioinformatics from the University of Michigan in 2011, where he worked on structural bioinformatics methods for computational drug design

    Abstract:
    Late-stage drug attrition rates in oncology remain higher than in other therapeutic areas. To reduce attrition, it is critical to identify appropriate drug targets and pre-clinical models. The integrative analysis framework was designed to systematically compute associations among driver mutations, fusions and copy alterations to define the driver aberration landscape of common cancers, then correlate the drivers to clinical metadata. Our driver selection methodology was developed through an interrogation of genomic aberrations in a training set of gold standard oncogenes such as EGFR, ALK and PIK3CA, and tumor suppressors such as TP53 and PTEN. The resulting platform was used to rank genes through an assessment of driver genomic aberrations, associations with patient survival, and potential clinical actionability. In this session, Dr. Khazanov will highlight proof of concept identification of a potentially clinically relevant candidate driver gene using a novel systematic integrative analysis of multi-dimensional cancer genomic data.

    Show Resources
    Loading Comments...